FrancophonIA/ELRC3.0 huggingface dataset:
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each implant contains 16 mg afamelanotide.
Croatian: Svaki implantat sadrži 16 mg afamelanotida.
English: Eyelid oedema Ocular hyperaemia Dry eye
Croatian: okularna hiperemija, suho oko, prezbiopija,
English: - decreased appetite; - fatigue (tiredness), - dizziness, drowsiness and weakness; - hot flushes; - upper respiratory tract infections (colds).
Croatian: - iscrpljenost (umor) - omaglica, omamljenost i slabost
English: Lip swelling
Croatian: (α-MSH).
English: Pain in extremity Muscle spasm Musculoskeletal pain Musculoskeletal stiffness Joint stiffness Groin pain
Croatian: mišićno-koštana ukočenost, ukočenost zglobova,
English: - Decrease white blood cells, abnormal liver function tests, decreased iron binding, increased cholesterol, increased sugar level, decreased blood iron level, increased blood pressure, blood in urine
Croatian: - Smanjenje broja bijelih krvnih stanica, abnormalan test funkcije jetre, smanjeno vezanje željeza,
English: Neoplasms benign, malignant and
Croatian: san slabe kvalitete, disgeuzija,
English: Cardiac disorders
Croatian: Krvožilni poremećaji
English: Nausea
Croatian: - mučnina
English: Injection site haematoma Injection site irritation
Croatian: Hematom na mjestu implantata
English: NAME OF THE MEDICINAL PRODUCT SCENESSE 16 mg implant afamelanotide
Croatian: Uputa o lijeku: Informacije za bolesnika SCENESSE 16 mg implantat afamelanotid
English: Infections and infestations
Croatian: - proljev i povraćanje
English: - Infected hair follicle, fungal infection, urinary tract infection
Croatian: Infekcije i infestacije infekcija gornjih dišnih putova influenca, gastrointestinalna infekcija, gastroenteritis, folikulitis, kandidijaza, nazofaringitis,
English: The recommended dose is one tablet a day.
Croatian: Preporučena je doza jedna tableta na dan.
English: Further information on Biktarvy can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Više informacija o lijeku Biktarvy možete naći na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: What measures are being taken to ensure the safe and effective use of Biktarvy?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Biktarvy?
English: What is Biktarvy and what is it used for?
Croatian: Što je Biktarvy i za što se koristi?
English: What are the risks associated with Biktarvy?
Croatian: Koji su rizici povezani s lijekom Biktarvy?
English: Other information about Biktarvy
Croatian: Ostale informacije o lijeku Biktarvy
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Biktarvy have been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Biktarvy nalaze se u sažetku opisa svojstava lijeka i u uputi o lijeku.
English: Side effects reported with Biktarvy are carefully evaluated and any necessary action taken to protect patients.
Croatian: Nuspojave prijavljene za lijek Biktarvy pažljivo se procjenjuju i poduzimaju se potrebne mjere za zaštitu bolesnika.
English: Why is Biktarvy authorised in the EU?
Croatian: Zašto je lijek Biktarvy odobren u EU-u?
English: Side effects were similar to those of medicines of the same class.
Croatian: Nuspojave su slične nuspojavama drugih lijekova iz iste skupine.
English: Biktarvy (bictegravir / emtricitabine / tenofovir alafenamide)
Croatian: Biktarvy (biktegravir/emtricitabin/tenofoviralafenamid)
English: It is only used in patients where the virus has not developed resistance to a class of HIV medicines called integrase inhibitors, or to tenofovir or emtricitabine.
Croatian: Primjenjuje se samo u bolesnika u kojih virus nije razvio rezistenciju na skupinu lijekova za liječenje HIV-a koji se nazivaju inhibitori integraze, ili na tenofovir ili emtricitabin.
English: The European Medicines Agency therefore decided that Biktarvy's benefits are greater than its risks and it can be authorised for use in the EU.
Croatian: Europska agencija za lijekove stoga je zaključila da koristi lijeka Biktarvy nadmašuju s njim povezane rizike te da lijek može biti odobren za primjenu u Europskoj uniji.
English: For more information about using Biktarvy, see the package leaflet or contact your doctor or pharmacist.
Croatian: Za više informacija o primjeni lijeka Biktarvy pogledajte uputu o lijeku ili se obratite liječniku ili ljekarniku.
English: Biktarvy was shown to be as effective as comparator antiviral medicines.
Croatian: Lijek Biktarvy pokazao se jednako učinkovitim kao i usporedni antivirusni lijekovi.
English: As for all medicines, data on the use of Biktarvy are continuously monitored.
Croatian: Kao za sve lijekove, podaci o primjeni lijeka Biktarvy kontinuirano se prate.
English: Biktarvy contains three active substances which work in different ways against HIV:
Croatian: Biktarvy sadrži tri djelatne tvari koje djeluju protiv HIV-a na različite načine:
English: It blocks an enzyme called integrase that is needed by the HIV virus to make new copies of itself in the body.
Croatian: On inhibira enzim naziva integraza koji je virusu HIV-a potreban da stvori nove kopije samoga sebe u tijelu.
English: The most common side effects with Biktarvy (which may affect around 1 in 20 people) are headache, diarrhoea and nausea (feeling sick).
Croatian: Najčešće nuspojave lijeka Biktarvy (koje se mogu javiti u otprilike 1 na 20 osoba) su glavobolja, proljev i mučnina (osjećaj slabosti).
English: The benefits of Biktarvy in the treatment of HIV infection were investigated in four main studies.
Croatian: Koristi lijeka Biktarvy u liječenju infekcije HIV-om istraživane su u okviru četiriju glavnih ispitivanja.
English: Biktarvy is an antiviral medicine used to treat adults infected with human immunodeficiency virus 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
Croatian: Biktarvy je antivirusni lijek koji se primjenjuje za liječenje odraslih osoba zaraženih virusom humane imunodeficijencije tipa 1 (HIV-1), virusom koji uzrokuje sindrom stečene imunodeficijencije (AIDS).
English: An overview of Biktarvy and why it is authorised in the EU
Croatian: Pregled informacija o lijeku Biktarvy i zašto je odobren u EU-u
English: Tenofovir is a nucleotide reverse transcriptase inhibitor (NRTI), which means that it blocks the activity of reverse transcriptase, another enzyme of the virus that allows it to reproduce itself.
Croatian: Tenofovir je nukleotidni inhibitor reverzne transkriptaze (NRTI), što znači da blokira djelovanje reverzne transkriptaze, još jednog enzima virusa koji virusu omogućuje množenje.
English: • Bictegravir is a type of antiviral agent called an ‘integrase inhibitor'.
Croatian: • Biktegravir je vrsta antivirusne tvari koja se naziva „inhibitor integraze”.
English: Biktarvy does not cure HIV-1 infection or AIDS, but it can hold off damage to the immune system and the development of infections and diseases associated with AIDS.
Croatian: Biktarvy ne može izliječiti infekciju HIV-om ili AIDS, ali može privremeno zaustaviti narušavanje imunosnog sustava i razvoj infekcija i bolesti povezanih s AIDS-om.
English: Biktarvy is available as tablets, each containing 50 mg bictegravir, 200 mg emtricitabine, and 25 mg tenofovir alafenamide.
Croatian: Lijek Biktarvy dostupan je u obliku tableta koje sadrže 50 mg biktegravira, 200 mg emtricitabina i 25 mg tenofoviralafenamida.
English: • Emtricitabine is another type of NRTI (a nucleoside reverse transcriptase inhibitor) and it works in the same way as tenofovir.
Croatian: • Emtricitabin je druga vrsta NRTI-ja (nukleotidni inhibitor reverzne transkriptaze) i djeluje na isti način kao i tenofovir.
English: Two studies involved adults infected with HIV-1 who had not been treated previously, and looked at the numbers whose viral load (the amount of HIV-1 in the blood) was reduced to less than 50 copies per ml after 48 weeks of treatment.
Croatian: Dva ispitivanja obuhvatila su odrasle osobe zaražene virusom HIV-1 koje prethodno nisu bile liječene, a promatrao se broj bolesnika u kojih se virusno opterećenje (količina virusa HIV-1 u krvi) smanjilo na manje od 50 kopija/ml nakon 48 tjedana liječenja.
English: Overall, 92% of patients taking Biktarvy (290 out of 314) achieved viral load reduction, compared with 93% (293 out of 315) of patients who achieved it with the comparator.
Croatian: Ukupno gledano, 92 % bolesnika koji su primali lijek Biktarvy (290 od 314) postiglo je smanjenje virusnog opterećenja, u usporedbi s 93 % (293 od 315) bolesnika koji su to postigli s usporednim lijekom.
English: Biktarvy can only be obtained with a prescription and treatment should be started by a doctor who has experience in the management of HIV infection.
Croatian: Biktarvy se izdaje samo na liječnički recept, a liječenje mora započeti liječnik s iskustvom u liječenju infekcije HIV-om.
English: Biktarvy must not be used together with rifampicin (an antibiotic) or with St. John's wort (a herbal medicine used for treating depression).
Croatian: Biktarvy se ne smije koristiti zajedno s rifampicinom (antibiotik) ili gospinom travom (biljni pripravak za liječenje depresije).
English: Two other studies involved previously treated patients in whom the viral load was already lower than 50 copies per ml, and looked at whether it increased above this level 48 weeks after patients were switched from their previous HIV treatment to Biktarvy.
Croatian: U drugim dvama ispitivanjima na prethodno liječenim bolesnicima u kojih je početno virusno opterećenje bilo manje od 50 kopija/ml proučavano je je li se ono povećalo iznad te razine 48 tjedana nakon što su bolesnici prebačeni sa svoje prethodne terapije za liječenje HIV-a na lijek Biktarvy.
English: In the second study, the viral load went above the threshold in 2% (5 out of 290) of patients switched to Biktarvy, and in 2% (5 out of 287) of patients who stayed on their previous treatment (‘boosted' atazanavir or darunavir plus either emtricitabine/tenofovir or abacavir/lamivudine).
Croatian: U drugom ispitivanju premašen je prag vrijednosti virusnog opterećenja u 2 % (5 od 290) bolesnika prebačenih na lijek Biktarvy, te u 2 % (5 od 287) bolesnika koji su nastavili s prethodnom terapijom (atazanavir ili darunavir pojačani emtricitabinom i tenofovirom ili abakavirom i lamivudinom).
English: What benefits of Biktarvy have been shown in studies?
Croatian: Koje su koristi lijeka Biktarvy dokazane u ispitivanjima?
English: In one study, the percentage of patients with viral load greater than or equal to 50 copies/ml was 1% (3 out of 282) of patients who switched to Biktarvy, compared with 0.5% (1 out of 281) of patients who stayed on their previous treatment (dolutegravir, abacavir, lamivudine).
Croatian: U jednom ispitivanju udio bolesnika u kojih je vrijednost virusnog opterećenja bila veća od ili jednaka 50 kopija/ml iznosio je 1 % (3 od 282) bolesnika prebačenih na lijek Biktarvy, u usporedbi s 0,5 % (1 od 281) bolesnika koji su nastavili s prethodnom terapijom (dolutegravir, abakavir, lamivudin).
English: How is Biktarvy used?
Croatian: Kako se Biktarvy koristi?
English: The second study compared Biktarvy with dolutegravir plus emtricitabine/tenofovir alafenamide in 645 patients: 89% (286 out of 320) of patients taking Biktarvy achieved satisfactory viral load reduction, compared with 93% (302 out of 325) of patients on the comparator.
Croatian: U drugom ispitivanju na 645 bolesnika, lijek Biktarvy uspoređen je s dolutegravirom u kombinaciji s emtricitabinom i tenofoviralafenamidom: 89 % (286 od 320) bolesnika koji su primali Biktarvy postiglo je zadovoljavajuće smanjenje virusnog opterećenja, u usporedbi s 93 % (302 od 325) bolesnika koji su primali usporedni lijek.
English: In the first study, Biktarvy was compared with another antiviral medicine containing abacavir, dolutegravir and lamivudine in 629 patients.
Croatian: U prvom ispitivanju na 629 bolesnika, lijek Biktarvy uspoređen je s drugim antivirusnim lijekom koji je sadržavao abakavir, dolutegravir i lamivudin.
English: How does Biktarvy work?
Croatian: Kako djeluje Biktarvy?
English: Biktarvy contains the active substances bictegravir, emtricitabine and tenofovir alafenamide.
Croatian: Biktarvy sadrži djelatne tvari biktegravir, emtricitabin i tenofoviralafenamid.
English: For the full list of side effects of Biktarvy, see the package leaflet.
Croatian: Potpuni popis nuspojava pri primjeni lijeka Biktarvy potražite u uputi o lijeku.
English: Pregnancy rate 0.9% 1.3% 1.4% 6.4% 5.7%
Croatian: Broj trudnoća Stopa trudnoća 0,9% 1,3% 1,4% 6,4% 5,7%
English: When should emergency contraception be used?
Croatian: Kada se koristi hitna kontracepcija?
English: Ask your doctor or pharmacist for advice on alternative methods of emergency contraception.
Croatian: Obratite se svom liječniku ili ljekarniku za savjet o alternativnim metodama hitne kontracepcije.
English: [The information below should be added in this section together with the two tables which follow]
Croatian: [Informacije u nastavku dodaju se u ovaj dio zajedno s dvama tablicama koje slijede]
English: [The existing product information shall be amended (insertion, replacement or deletion of the text as appropriate) to reflect the agreed wording as provided below]
Croatian: [Postojeće informacije o lijeku mijenjaju se (uvrštenje, zamjena ili brisanje teksta po potrebi) kako bi odrazile usuglašeni tekst naveden u nastavku]
English: Pregnancy rate (95% CI) according to weight categories Weight (kg) N total N pregnancies
Croatian: Stopa trudnoća (95% CI) prema kategorijama tjelesne težine Tjelesna težina (kg) Ukupan broj korisnica
English: Therefore, <invented name> is still recommended for all women regardless of their weight or BMI.
Croatian: Stoga se <zaštićeno ime> i dalje preporučuje za sve žene, bez obzira na tjelesnu težinu ili ITM.
English: In all women, emergency contraception should be taken as soon as possible after unprotected intercourse.
Croatian: Sve žene hitnu kontracepciju trebaju uzeti što ranije nakon nezaštićenog spolnog odnosa.
English: Both meta-analyses excluded intake later than 72 hours after unprotected intercourse (i.e. off-label use of levonorgestrel) and women who had further acts of unprotected intercourse.
Croatian: U obje meta-analize nisu bili uključeni uzimanje kontraceptiva više od 72 sata nakon nezaštićenog spolnog odnosa (tj. neodobrena uporaba levonorgestrela) i žene koje su imale daljnje nezaštićene spolne odnose.
English: In three WHO studies no trend for a reduced efficacy with increasing body weight/BMI was observed (Table 1), whereas in the two other studies (Creinin et al., 2006 and Glasier et al., 2010) a reduced contraceptive efficacy was observed with increasing body weight or BMI (Table 2).
Croatian: U trima ispitivanjima Svjetske zdravstvene organizacije nije primijećen trend smanjenja djelotvornosti s porastom tjelesne težine/ITM-a (Tablica 1), dok je u dvama drugim ispitivanjima (Creinin i sur., 2006 te Glasier i sur., 2010) primijećena smanjena djelotvornost kontraceptiva s porastom tjelesne težine ili ITM-a (Tablica 2).
English: Table 1: Meta-analysis on three WHO studies (Von Hertzen et al., 1998 and 2002; Dada et al., 2010)
Croatian: Tablica 1: Meta-analiza triju ispitivanja SZO-a (Von Hertzen i sur., 1998 i 2002; Dada i sur., 2010)
English: Table 2: Meta-analysis on studies of Creinin et al., 2006 and Glasier et al., 2010
Croatian: Tablica 2: Meta-analiza ispitivanja koja su proveli Creinin i sur., 2006 te Glasier i sur., 2010
English: In all women, emergency contraception should be taken as soon as possible after unprotected intercourse, regardless of the woman's body weight or BMI.
Croatian: Sve žene hitnu kontracepciju trebaju uzeti što ranije nakon nezaštićenog spolnog odnosa, bez obzira na tjelesnu težinu ili ITM.
English: Take special care with <invented name> <strength> tablet
Croatian: Budite posebno oprezni s <zaštićeno ime> <jačina> tabletama
English: B. Package leaflet
Croatian: Dodatak III
English: [The information below should be deleted together with the table] In clinical trials, contraceptive efficacy was reduced in women weighing 75 kg or more and levonorgestrel was not effective in women who weighed more than 80 kg (see sections 4.2 and 4.4).
Croatian: [Informacije u nastavku se brišu, zajedno s tablicom] U kliničkim je ispitivanjima učinkovitost kontraceptiva bila smanjena u žena tjelesne težine od 75 kg ili više, a levonogestrel nije bio učinkovit u žena tjelesne težine veće od 80 kg (vidjeti dijelove 4.2 i 4.4).
English: Limited and inconclusive data suggest that there may be reduced efficacy of <invented name> with increasing body weight or body mass index (BMI) (see section 5.1).
Croatian: Ograničeni podaci koji ne dopuštaju donošenje konačnih zaključaka upućuju na to da se djelotvornost <zaštićeno ime> može smanjivati s porastom tjelesne težine ili indeksa tjelesne mase (ITM) (vidjeti dio 5.1).
English: Studies suggest that <invented name> is less effective in women weighing 75 kg or more and not effective in women weighing more than 80 kg.
Croatian: Ispitivanja upućuju na to da je lijek <zaštićeno ime> manje učinkovit u žena tjelesne težine od 75 kg ili više te da nije učinkovit u žena tjelesne težine veće od 80 kg.
English: There is some evidence that <invented name> may be less effective with increasing body weight or body mass index (BMI), but these data were limited and inconclusive.
Croatian: Neki dokazi upućuju na to da se djelotvornost <zaštićeno ime> može smanjivati porastom tjelesne težine ili indeksa tjelesne mase (ITM), no ti su podaci nedostatni za donošenje konačnih zaključaka.
English: For Levonorgestrel-containing emergency contraceptive medicinal products A. Summary of product characteristics
Croatian: Za hitne kontraceptive koji sadrže levonorgestrel A.
English: - if you weigh 75 kg or more (see “What <invented name> <strength> tablet is and what it is used for” for further details)
Croatian: - ako imate 75 kg ili više (za više informacija pogledajte dio
English: There is limited and inconclusive data on the effect of high body weight/high BMI on the contraceptive efficacy.
Croatian: Podaci o utjecaju velike tjelesne težine/visokog ITM-a na učinkovitost kontraceptiva su ograničeni i nedostatni za donošenje konačnih zaključaka.
English: Annex III Amendments to relevant sections of the summary of product characteristics and package leaflet
Croatian: Izmjene odgovarajućih dijelova sažetaka opisa svojstava lijeka i uputa o lijeku
English: BEFORE YOU USE <invented name> <strength> TABLET
Croatian: <zaštićeno ime> <jačina> TABLETE
English: [the phrase below should be deleted from this section] Special population: body weight 75 kg or more
Croatian: Posebne populacije: tjelesna težina od 75 kg ili više
English: - If you are more than 3 months pregnant.
Croatian: - Ako ste dulje od 3 mjeseca trudni.
English: Al/Al blisters:
Croatian: Al/Al blisteri:
English: Cumulative urinary excretion is < 1% of dose.
Croatian: Kumulativna urinarna ekskrecija je <1% doze.
English: 250 tablets
Croatian: 250 tableta
English: Currently available data are described in section 5.1 and 5.2 but no recommendation on a posology can be made.
Croatian: Trenutno dostupni podaci opisani su u dijelovima 5.1 i 5.2, ali se ne mogu dati preporuke za doziranje.
English: The tablets should be swallowed with some water or other non-alcoholic drink.
Croatian: Tablete treba progutati s malo vode ili s drugim bezalkoholnim pićem.
English: (It is also better to avoid Telmisartan Actavis in early pregnancy - see pregnancy section.)
Croatian: (Također je bolje izbjegavati Telmisartan Actavis u ranoj trudnoći - vidjeti dio o trudnoći.)
English: You can take Telmisartan Actavis with or without food.
Croatian: Možete uzimati Telmisartan Actavis sa ili bez hrane.
English: Thus it is important to regularly measure blood pressure to verify if it is within the normal range.
Croatian: Stoga je važno redovito mjeriti krvni tlak i pratiti je li unutar normalnog raspona.
English: If you forget to take your medicine you should take the dose as soon as you remember on the same day.
Croatian: Ako ste zaboravili uzeti lijek, isti dan uzmite svoju dozu čim se sjetite.
English: It is important that you take Telmisartan Actavis every day until your doctor tells you otherwise.
Croatian: Telmisartan Actavis svaki dan, dok Vam liječnik ne kaže drugačije.
English: The safety data from this study in patients aged 6 to < 18 years appeared generally similar to that observed in adults.
Croatian: Podaci o sigurnosti iz ovog ispitivanja na bolesicima u dobi od 6 do < 18 godina starosti smatrale su se općenito sličnima onima primijećenima kod odraslih osoba.
English: If you feel dizzy or tired, do not drive or use machines.
Croatian: Ako osjećate omaglicu ili umor, ne upravljajte vozilima ili strojevima.
English: When considering raising the dose, it must be borne in mind that the maximum antihypertensive effect is generally attained four to eight weeks after the start of treatment (see section 5.1).
Croatian: Kada se razmatra povišenje doze, mora se uzeti u obzir da se maksimalni antihipertenzivni učinak općenito postiže četiri do osam tjedana nakon početka liječenja (vidjeti dio 5.1).
English: If you have the impression that the effect of Telmisartan Actavis is too strong or too weak, talk to your doctor or pharmacist.
Croatian: Ako mislite da je učinak lijeka Telmisartan Actavis prejak ili preslab, razgovarajte sa svojim liječnikom ili ljekarnikom.
English: Telmisartan is largely bound to plasma protein (> 99.5%), mainly albumin and alpha-1 acid glycoprotein.
Croatian: Telmisartan se uvelike veže na proteine plazme (>99,5%), uglavnom albumin i alfa-1 kiselinski glikoprotein.
English: - If you are taking an ACE-inhibitor or aliskiren (see also information under the headings “Do not take Telmisartan Actavis” and “Warnings and precautions”).
Croatian: - Ako uzimate ACE inhibitor ili aliskiren (vidjeti također informacije pod naslovima „Nemojte uzimati Telmisartan Actavis“ i „Upozorenja i mjere opreza“).
English: By 3 hours after administration plasma concentrations are similar whether telmisartan is taken fasting or with food.
Croatian: Do 3 sata nakon primjene, koncentracije u plazmi su slične bez obzira uzima li se telmisartan natašte ili s hranom.
English: The maximum plasma concentration (Cmax) and, to a smaller extent, the area under the plasma concentration-time curve (AUC) increase disproportionately with dose.
Croatian: Maksimalna koncentracija u plazmi (Cmax) i, u manjoj mjeri, površina ispod krivulje koncentracije u plazmi-vrijeme (AUC), povećava se disproporcionalno s dozom.
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 30.09.2010
Croatian: Datum prvog odobrenja: 30.09.2010.
English: See also information under the heading “Do not take Telmisartan Actavis”.
Croatian: Vidjeti također informacije pod naslovom „Nemojte uzimati Telmisartan Actavis“.
English: Your doctor will normally advise you to stop taking Telmisartan Actavis before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Telmisartan Actavis.
Croatian: Liječnik će Vam obično savjetovati da prestanete uzimati Telmisartan Actavis prije nego ostanete trudni ili čim saznate da ste trudni te će Vam savjetovati uzimanje drugog lijeka umjesto lijeka Telmisartan Actavis.
English: The occurrence of hyperkalaemia depends on associated risk factors.
Croatian: Pojava hiperkalemije ovisi o udruženim čimbenicima rizika.
English: In case of surgery or anaesthesia, you should tell your doctor that you are taking Telmisartan Actavis.
Croatian: U slučaju kirurškog zahvata ili anestezije, trebate obavijestiti svog liječnika da uzimate Telmisartan
English: Whilst there is no controlled epidemiological data on the risk with angiotensin II receptor antagonists, similar risks may exist for this class of drugs.
Croatian: Iako nema kontroliranih epidemioloških podataka o riziku uz antagoniste receptora angiotenzina II, slični rizici mogu postojati za ovu skupinu lijekova.